VisusNano

VisusNano operates in the medical technology sector, focusing on innovative solutions for cataract surgery. The company has developed the Visi Lens, a biodegradable intraocular lens (IOL) that releases anti-inflammatory drugs directly into the eye, eliminating the need for postoperative eye drops. This technology aims to improve patient outcomes by reducing complications such as postoperative infections and inflammation, which are common after cataract surgery. The primary clients are both human and veterinary patients undergoing cataract surgery. VisusNano's market includes ophthalmologists, veterinary surgeons, and healthcare providers. The business model revolves around the sale of Visi Lens to medical institutions and clinics, generating revenue through direct sales and potential licensing agreements. By addressing the compliance issues associated with postoperative eye drop administration, particularly in elderly patients, VisusNano aims to enhance the overall effectiveness of cataract treatments.

Keywords: cataract surgery, intraocular lens, biodegradable, drug release, anti-inflammatory, postoperative care, ophthalmology, veterinary, medical technology, patient compliance.